It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Optoacoustic imaging is a new biomedical imaging technology with clear benefits over traditional optical imaging and ultrasound. While the imaging technology has improved since its initial development, the creation of dedicated contrast agents for optoacoustic imaging has been stagnant. Current exploration of contrast agents has been limited to standard commercial dyes that have already been established in optical imaging applications. While some of these compounds have demonstrated utility in optoacoustic imaging, they are far from optimal and there is a need for contrast agents with tailored optoacoustic properties. The synthesis, encapsulation within tumor targeting silica nanoparticles and applications in in vivo tumor imaging of optoacoustic contrast agents are reported.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Georgia State University, Department of Chemistry, Atlanta, USA (GRID:grid.256304.6) (ISNI:0000 0004 1936 7400)
2 Oklahoma Health Science Center, Department of Surgery, Oklahoma City, USA (GRID:grid.256304.6); Stephenson Cancer Center, Oklahoma Health Science Center, Oklahoma City, USA (GRID:grid.266900.b) (ISNI:0000 0004 0447 0018)
3 Stephenson Cancer Center, Oklahoma Health Science Center, Oklahoma City, USA (GRID:grid.266900.b) (ISNI:0000 0004 0447 0018); University of Oklahoma, Department of Biomedical Engineering, Norman, USA (GRID:grid.266900.b) (ISNI:0000 0004 0447 0018)
4 Georgia State University, Department of Chemistry, Atlanta, USA (GRID:grid.256304.6) (ISNI:0000 0004 1936 7400); Georgia State University, Center for Diagnostics and Therapeutics, Atlanta, USA (GRID:grid.256304.6) (ISNI:0000 0004 1936 7400)
5 University of Oklahoma, Department of Biomedical Engineering, Norman, USA (GRID:grid.266900.b) (ISNI:0000 0004 0447 0018)
6 Oklahoma Health Science Center, Department of Pathology, Oklahoma City, USA (GRID:grid.266900.b)
7 Virginia Tech University, Department of Mechanical Engineering, Blacksburg, USA (GRID:grid.438526.e) (ISNI:0000 0001 0694 4940)
8 Oklahoma Health Science Center, Department of Surgery, Oklahoma City, USA (GRID:grid.438526.e); Stephenson Cancer Center, Oklahoma Health Science Center, Oklahoma City, USA (GRID:grid.266900.b) (ISNI:0000 0004 0447 0018); University of Oklahoma, Department of Biomedical Engineering, Norman, USA (GRID:grid.266900.b) (ISNI:0000 0004 0447 0018); Wake Forest University, Department of Cancer Biology, Winston-Salem, USA (GRID:grid.241167.7) (ISNI:0000 0001 2185 3318)